Protection of SARS‐CoV‐2 Infection by Targeting Viral Spike Protein With De Novo Designed ACE2‐Derived Undecapeptide
Journal of Peptide Science · 2026-07 · 32 (7)
DOI: 10.1002/psc.70097 ↗At a glance
Journal article in Journal of Peptide Science, published online on 2026-05-27. Written by Anindya Dutta and 9 co-authors. Institution: BITS-BioCyTIH Foundation, Birla Institute of Technology and Science (BITS) Pilani, Mormugao, South Goa, India. Major MEDLINE topics: Spike Glycoprotein, Coronavirus, SARS-CoV-2, Peptidyl-Dipeptidase A, Antiviral Agents. 44 references. Funded by: BITS-BioCyTIH Foundation, Bose Institute.
Abstract (original language)
The envelope‐anchored trimeric spike protein of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) mediates the attachment and entry of the virus within human cells by utilizing the angiotensin converting enzyme 2 (ACE2) as a receptor, present in the epithelial cells of the upper respiratory tract and lungs. The ACE2 interaction interface with the SARS‐CoV‐2 spike protein was utilized to design an ACE2‐derived peptide sequence (FD11) that targeted the viral spike protein. It was found to be non‐cell penetrating, while in vivo studies revealed the non‐cytotoxic nature of the peptide molecule. The minimum effective concentration of the peptide was found to be 10 μM with 95% cell viability in Vero E6 cell line. The IC 50 of the peptide was found to be around 6.4 μM. Treatment of the peptide in SARS‐CoV‐2 infected Vero E6 cells was found to decrease the infectivity as compared to control. This presents a simple approach where host‐pathogen protein interaction‐interface derived peptides can be used for binding with substrate macromolecules to target and modulate pathogen infectivity.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- BITS-BioCyTIH Foundation, Birla Institute of Technology and Science (BITS) Pilani, Mormugao, South Goa, India.
- Bose Institute, Kolkata, West Bengal, India.
- CSIR-Indian Institute of Chemical Biology (IICB), Kolkata, West Bengal, India.
- Barasat Cancer Research and Welfare Centre, Kolkata, West Bengal, India.
Funding
- BITS-BioCyTIH Foundation
- Bose Institute
Cite
APA
Dutta, A., Banerjee, N., Sarkar, S., Sen, A., Chakrabarti, P., Dutta, A., Jana, K., Mukherjee, G., Chattopadhyay, S., & Chatterjee, S. (2026). Protection of SARS‐CoV‐2 Infection by Targeting Viral Spike Protein With De Novo Designed ACE2‐Derived Undecapeptide. Journal of Peptide Science, 32(7). https://doi.org/10.1002/psc.70097
Vancouver
Dutta A, Banerjee N, Sarkar S, Sen A, Chakrabarti P, Dutta A, et al. Protection of SARS‐CoV‐2 Infection by Targeting Viral Spike Protein With De Novo Designed ACE2‐Derived Undecapeptide. Journal of Peptide Science. 2026;32(7). doi:10.1002/psc.70097
BibTeX
@article{Dutta2026,
author = {Dutta, Anindya and Banerjee, Nilanjan and Sarkar, Soushruti and Sen, Abhishek and Chakrabarti, Partha and Dutta, Ananya and Jana, Kuladip and Mukherjee, Gopeswar and Chattopadhyay, Samit and Chatterjee, Subhrangsu},
title = {Protection of SARS‐CoV‐2 Infection by Targeting Viral Spike Protein With De Novo Designed ACE2‐Derived Undecapeptide},
journal = {Journal of Peptide Science},
year = {2026},
volume = {32},
number = {7},
doi = {10.1002/psc.70097}
}
EUVIMED